Stories
Mankind Pharma to Acquire 70% Stake in Cancer Therapy Firm ACTx for Rs 511 Crore
C
CNBC TV18•15-10-2026, 22:32
Mankind Pharma to Acquire 70% Stake in Cancer Therapy Firm ACTx for Rs 511 Crore
- •Mankind Pharma has agreed to acquire a 70 percent stake in Belgium-based Armed Cell Therapeutics B.V. for 48 million euros, marking its entry into next-generation cancer cell therapies.
- •The acquisition will be executed through Mankind Pharma Netherlands B.V., with the cash consideration to be paid in installments subject to regulatory approvals.
- •ACTx specializes in developing next-generation armed CAR-T therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer.
- •The startup is founded by prominent industry veterans including Paul Stoffels, John Mellors, and Peter Verhaeghe, with research operations spanning the US and Europe.
- •Mankind Pharma aims to leverage this strategic investment to build a global pipeline of breakthrough therapies and make advanced treatments accessible in India and worldwide.
Key Questions Answered
Mankind Pharma has agreed to acquire a 70% stake in the Belgium-based cancer therapy firm Armed Cell Therapeutics B.V. (ACTx) for €48 million, which is approximately ₹511.18 crore.
ACTx is developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies known as armed CAR-T, focusing on lead programmes for non-Hodgkin lymphoma and small cell lung cancer as well as exploring in vivo CAR-T.
The founders of ACTx include Paul Stoffels, John Mellors, and Peter Verhaeghe, who bring extensive industry and academic leadership experience from organizations like Johnson & Johnson, Galapagos, and argenx.
